Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

TOF Mass Spectrometer

By Drug Discovery Trends Editor | September 2, 2008

Bruker Daltonics maXisThe maXis from Bruker Daltonics is an Electrospray Ultra-High Resolution tandem TOF (UHR-Qq-TOF) mass spectrometer for applications including small molecule identification, metabolomics, quantitative proteomics, as well as biomarker discovery and validation.

The maXis offers ultra-high resolution of 40,000 – 60,000 FWHM over a broad mass range, MS and MS/MS mass accuracy typically between 600 and 800 ppb, at speeds of up to 20 full spectra per second.  It also offers 20 Hz full spectra acquisition at ultra-high mass resolution for high-speed liquid      chromatography; novel IonCooler technology delivers excellent MS/MS sensitivity over a broad m/z range; high dynamic range of five orders of magnitude for trace detection in complex mixtures; sub-ppm mass accuracy in both MS and MS/MS mode for high confidence IDs; and SmartFormula 3D unambiguous determination of molecular sum formulae for molecules up to 1 kDalton.

“Now ultra-high resolution mass spectrometry over broad mass ranges is finally compatible with ultra performance liquid chromatography,” explained Bruker Daltonics Executive Vice President Dr. Ian Sanders. “Our new maXis indeed represents a major step forward in tandem mass spectrometry, offering a no-compromise solution for exceptional accurate mass, ultra-high resolution over a broad mass range and high sensitivity MS and MS/MS analysis at a speed able to take full advantage of modern, fast liquid chromatography or fast capillary electrophoresis separations.”

Bruker Daltonics


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50